- Home
- AU vs BIO Comparison
AU vs BIO Comparison
Compare AU & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- BIO
- Stock Information
- Founded
- AU 1944
- BIO 1952
- Country
- AU United States
- BIO United States
- Employees
- AU N/A
- BIO N/A
- Industry
- AU Precious Metals
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- AU Basic Materials
- BIO Industrials
- Exchange
- AU Nasdaq
- BIO Nasdaq
- Market Cap
- AU 30.2B
- BIO 7.7B
- IPO Year
- AU 1972
- BIO N/A
- Fundamental
- Price
- AU $64.61
- BIO $286.26
- Analyst Decision
- AU Buy
- BIO Strong Buy
- Analyst Count
- AU 5
- BIO 4
- Target Price
- AU $47.30
- BIO $333.50
- AVG Volume (30 Days)
- AU 3.3M
- BIO 236.7K
- Earning Date
- AU 11-06-2025
- BIO 10-29-2025
- Dividend Yield
- AU 1.43%
- BIO N/A
- EPS Growth
- AU 1303.37
- BIO N/A
- EPS
- AU 3.81
- BIO 11.49
- Revenue
- AU $7,649,000,000.00
- BIO $2,554,200,000.00
- Revenue This Year
- AU $62.30
- BIO $2.12
- Revenue Next Year
- AU N/A
- BIO $2.90
- P/E Ratio
- AU $16.95
- BIO $24.92
- Revenue Growth
- AU 54.59
- BIO N/A
- 52 Week Low
- AU $22.45
- BIO $211.43
- 52 Week High
- AU $67.67
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- AU 67.01
- BIO 52.96
- Support Level
- AU $56.68
- BIO $276.49
- Resistance Level
- AU $67.67
- BIO $298.00
- Average True Range (ATR)
- AU 1.95
- BIO 7.95
- MACD
- AU 0.29
- BIO -2.02
- Stochastic Oscillator
- AU 75.70
- BIO 40.11
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.